UPDATE 1-Roche wins wider EU label for arthritis drug

June 8 (Reuters) – Roche (ROG.VX) said on Tuesday the European Commission had extended the label for its drug Roactemra to reduce the rate of progression of joint damage and improve physical function in patients with rheumatoid arthritis, when given in combination with the older drug methotrexate.

The move had been expected following a positive recommendation from the European Medicines Agency in April.

The drug, which is known as Actemra in the United States, is currently approved for use in combination with methotrexate to treat adults with moderate to severe rheumatoid arthritis who respond inadequately to other treatments.

The new label extension is a recognition that Roactemra can also inhibit structural damage to joints, reinforcing its effectiveness.

(Writing by Ben Hirschler)

Scientists uncover new trigger for chronic inflammation in rheumatoid arthritis

London, June 29 (ANI): Scientists at Imperial College London say that blocking a signal molecule made by the human body, which triggers the immune system into action, may make it possible to develop more effective treatments for rheumatoid arthritis.

Rheumatoid arthritis is the most common autoimmune disease that causes painful and persistent swelling in the joints, which can result in damage to the bone and cartilage.

Considering that around half of all patients do not respond to one or more of the treatments currently available, the researchers say that stopping the disease closer to the root of the problem could be the best way to treat it.

In their study paper, the researchers point out that the body responds to an infection by a microbe by turning on a molecular switch to set the immune system into action.

They say that their findings show that a signal molecule called tenascin-C can trigger the same molecular switch, and also activate the immune system.

They add that high levels of tenascin-C present in joints, therefore, may cause the activated immune system to attack the joint leading to the persistent inflammation of rheumatoid arthritis.

The researchers also reveal that the molecular switch called TLR4 is found on the surface of immune cells.

According to them, studies conducted in the past have shown that mice without TLR4 do not show chronic joint inflammation.

The team hope that scientists can develop new treatments that target the interaction between tenascin-C and TLR4, which may help to combat rheumatoid arthritis.

“Rheumatoid arthritis is a debilitating and painful disease and, unfortunately, there is no cure. Furthermore, current treatments are not effective for many patients,” Nature magazine quoted Dr. Kim Midwood, lead author of the study from the Kennedy Institute of Rheumatology at Imperial College London, as saying.

“We have uncovered one way that the immune system may be triggered to attack the joints in patients with rheumatoid arthritis. We hope our new findings can be used to develop new therapies that interfere with tenascin-C activation of the immune system and that these will reduce the painful inflammation that is a hallmark of this condition,” added Dr. Midwood.

The authors say that the next step will be to work out the precise mechanism by which tenascin-C increases these levels of inflammatory molecules in the human joint, and to find ways to inhibit this action.

A research article on their findings has been published in the journal Nature Medicine. (ANI)

Immune cells in rheumatoid arthritis patients have prematurely aged chromosomes

Washington, Mar 5 (ANI): Scientists at Emory University School of Medicine have discovered that T cells, or white blood cells, from patients with the autoimmune disease rheumatoid arthritis have prematurely aged chromosomes due to lack of structures called telomeres.

elomeres are structures that cap the ends of cells’ chromosomes, grow shorter with each round of cell division unless a specialized enzyme replenishes them.

It is important to maintain telomeres as they are thought to be important for healthy aging and cancer prevention.

T cells from patients with rheumatoid arthritis were found to have trouble turning on the enzyme that replenishes telomeres, when compared with cells from healthy people.

Reversing this defect could possibly help people prone to the disease maintain a balanced immune system.

Senior author Cornelia Weyand, MD, PhD said that in rheumatoid arthritis, T cells are chronically over-stimulated, invading the tissue of the joints and causing painful inflammation.

She claimed that in childhood, new T cells are continually produced in the thymus, but after about age 40, the thymus “involutes” – or shrinks and ceases to function. After that, the immune system has to make do with the pool of T cells it already has.

“What we see in rheumatoid arthritis is an aged and more restricted T cell repertoire. This biases the immune system toward autoimmunity,” she said.

Intrigued by earlier studies claiming that in rheumatoid arthritis, T cells tend to shift the molecules on their surface and function differently, the researchers wanted to study the mechanisms of T cells’ premature aging.

They found the answer in telomerase, the enzyme that renews telomeres and is necessary to prevent loss of genetic information after repeated cell division.

Telomerase adds short repeated DNA sequences to the ends of chromosomes to protect them. The enzyme is active in embryonic development but is usually switched off in adult cells. Many cancer cells reactivate it to enable runaway growth.

T cells are some of the very few cells in adults that can turn on telomerase when stimulated, probably because they have to divide many times and stay alive for decades.

Researchers found that T cells from patients with rheumatoid arthritis make 40 percent less telomerase enzyme when stimulated.

The cells came from 69 patients, 92 percent female, with an average age of 50, and were compared with cells from healthy people with similar demographics.

By shutting off a gene encoding part of the enzyme normal T cells were made vulnerable to programmed cell death, and transferring telomerase into patients’ T cells rescued them from dying.

Scientists said that the finding suggests that restoring defective telomerase to T cells could possibly help “reset” the immune system in rheumatoid arthritis.

The results are published online in Proceedings of the National Academy of Sciences. (ANI)